CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1,2:4,5] PYRAZINO [2,1-B] [1,3] OXAZEPINE-10-CARBOXAMIDE
CARRA, Ernest, A.,CHEN, Irene,KEATON, Katie, Ann,ZIA, Vahid
申请号：
USUS2015/036784
公开号：
WO2015/196137A1
申请日:
2015.06.19
申请国别(地区):
WO
年份:
2015
代理人:
摘要：
The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanpyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2 R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.La présente invention concerne des formes cristallines et des co-cristaux de (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13 a-octahydro-2,5-méthanpyrido[1,2:4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide, leurs formulations pharmaceutiques et leurs utilisations thérapeutiques. La présente invention concerne également de nouvelles formes cristallines (2R,5S,13 aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyle)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido[1,2:4,5]pyrazino[2,1-b] [1,3]oxazépin-8-olate de sodium Forme I
